Related Experiment Video
Updated: Apr 12, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Tocilizumab for refractory organising pneumonia associated with Sjögren's disease
Aurelien Justet1, Sebastien Ottaviani2, Philippe Dieudé2
1Department of Service de Pneumologie A, Hôpital Bichat-Claude Bernard, Paris, France Université Denis Diderot, Paris 7, Unité INSERM U1152, Paris, France.
Abstract:
Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Pancreatitis II: Collaborative Care
Assessment:
COPD: Management Using Bronchodilators and Corticosteroids

